Department of Interventional Ultrasound, Chinese PLA General Hospital, No.28 Fuxing Road, Haidian District, Beijing, China.
Department of Ultrasound, the First Affiliated Hospital of Dalian Medical University, Dalian, China.
Eur Radiol. 2023 Nov;33(11):7942-7951. doi: 10.1007/s00330-023-09802-x. Epub 2023 Jun 9.
To assess the safety and efficacy of ultrasound-guided thermal ablation for low-risk papillary thyroid microcarcinoma (PTMC) via a prospective multicenter study.
From January 2017 through June 2021, low-risk PTMC patients were screened. The management details of active surveillance (AS), surgery, and thermal ablation were discussed. Among patients who accepted thermal ablation, microwave ablation (MWA) was performed. The main outcome was disease-free survival (DFS). The secondary outcomes were tumor size and volume changes, local tumor progression (LTP), lymph node metastasis (LNM), and complication rate.
A total of 1278 patients were included in the study. The operation time of ablation was 30.21 ± 5.14 min with local anesthesia. The mean follow-up time was 34.57 ± 28.98 months. Six patients exhibited LTP at 36 months, of whom 5 patients underwent a second ablation, and 1 patient received surgery. The central LNM rate was 0.39% at 6 months, 0.63% at 12 months, and 0.78% at 36 months. Of the 10 patients with central LNM at 36 months, 5 patients chose ablation, 3 patients chose surgery and the other 2 patients chose AS. The overall complication rate was 1.41%, and 1.10% of patients developed hoarseness of the voice. All of the patients recovered within 6 months.
Thermal ablation of low-risk PTMC was observed to be safe and efficacious with few minor complications. This technique may help to bridge the gap between surgery and AS as treatment options for patients wishing to have their PTMC managed in a minimally invasive manner.
This study proved that microwave ablation is a safe and effective treatment method for papillary thyroid microcarcinoma.
Percutaneous US-guided microwave ablation of papillary thyroid microcarcinoma is a very minimally invasive treatment under local anesthesia during a short time period. The local tumor progression and complication rate of microwave ablation in the treatment of papillary thyroid microcarcinoma are very low.
通过前瞻性多中心研究评估超声引导下热消融治疗低危甲状腺微小乳头状癌(PTMC)的安全性和有效性。
2017 年 1 月至 2021 年 6 月,筛选低危 PTMC 患者。讨论主动监测(AS)、手术和热消融的管理细节。接受热消融的患者行微波消融(MWA)。主要结局为无病生存(DFS)。次要结局为肿瘤大小和体积变化、局部肿瘤进展(LTP)、淋巴结转移(LNM)和并发症发生率。
共纳入 1278 例患者。消融手术时间为 30.21±5.14min,行局部麻醉。中位随访时间为 34.57±28.98 个月。6 例患者在 36 个月时出现 LTP,其中 5 例接受了二次消融,1 例接受了手术。6 个月时中央区 LNM 发生率为 0.39%,12 个月时为 0.63%,36 个月时为 0.78%。10 例 36 个月时中央区 LNM 的患者中,5 例选择消融,3 例选择手术,另外 2 例选择 AS。总并发症发生率为 1.41%,1.10%的患者出现声音嘶哑。所有患者均在 6 个月内恢复。
低危 PTMC 的热消融是安全有效的,且并发症少。对于希望以微创方式治疗 PTMC 的患者,该技术可能有助于在手术和 AS 之间架起桥梁。
本研究证明,微波消融是治疗甲状腺微小乳头状癌的一种安全有效的治疗方法。
经皮超声引导下微波消融治疗甲状腺微小乳头状癌是一种非常微创的治疗方法,在局部麻醉下,在短时间内进行。微波消融治疗甲状腺微小乳头状癌的局部肿瘤进展和并发症发生率均很低。